"After conclusion in 2008 of our divestiture program, this transaction is a first step towards reinforcing our leading cardiac surgery franchises. This acquisition will be particularly exciting for Sorin Group’s United States business as it will reinforce our product offering and consolidate our position as the leading provider of innovative solutions for the cardiac surgery clinical community, ” said André-Michel Ballester, C.E.O. Sorin Group.
About the Sorin Group
The Sorin Group (www.sorin.com), is a global company and a leader in the treatment of cardiovascular diseases. The Company develops, manufactures and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders. With 3,500 employees worldwide, the Group focuses on three major therapeutic areas that include: cardiopulmonary bypass (extracorporeal circulation and autotransfusion systems), cardiac rhythm management, and heart valve repair and replacement. Every year, over 1 million patients are treated with the devices of Sorin Group in more than 80 countries.
For more information, please visit: www.sorin.com.
Contact:
Martine Konorski Director, Corporate Communications Sorin Group Tel: +33 (0)1 46 01 33 78 Mobile: +33 (0)6 76 12 67 73 e-mail: martine.konorski@sorin.com or Carla Vidra Investor Relations Sorin Group Tel: +39 02 69969716 e-mail: carla.vidra@sorin.com
